Structures made via cryo-EM give researchers insights into SARS-CoV-2, HIV, neurological disorders, cancer, and more.

By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

Explore what researchers can do with Cryo-EM

While some experts speculate the variant could be partially responsible for India’s current surge in SARS-CoV-2 infections, information about the effects of its mutations is only beginning to emerge.

Immunization had up to 77 percent efficacy in a Phase 2 clinical study of 450 children in Burkina Faso.

Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.

It’s unclear how long protections against infection will last from the initial vaccinations, and health authorities say additional jabs will likely be necessary.

The FDA and CDC are investigating a handful of reports of blood clots that occurred several days after people received the one-and-done shot.

Vaccinations with the Johnson & Johnson jab paused at several sites earlier this week after an unusual number of people experienced adverse reactions, but the CDC says there’s no cause for concern.

The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.

One hundred years after its invention, BCG has stood the test of time as a vaccine against tuberculosis.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.

Identifying molecular targets for SARS-CoV-2 therapeutics.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

The P.1 variant, which has also been detected in five US states, could be responsible for cases of reinfection, according to a preprint.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.

In a triumph for science, COVID-19 statistics are finally trending favorably in the US. We must make sure the rest of the world is not left behind.